A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called "BRAF" and available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799933. PF-07799933 comes as a tablet to take by mouth, 2 times a day. Depending on the part of the study, participants may also receive another study medicine: * People with melanoma or other solid tumors may also receive binimetinib. Binimetinib comes as a tablet to take by mouth, 2 times a day. * People with colorectal cancer may also receive cetuximab or cetuximab and mFOLFOX6 (Chemotherapy regimen). Cetuximab will be given weekly (or every two weeks) in the clinic as a shot given in the vein or port (intravenous, IV). Participants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zdiagnozowany zaawansowany guz lity (w tym pierwotny guz mózgu).
- •Posiadanie określonej zmiany w genie BRAF (V600 lub innej, klasy II/III).
- •Rak postępował mimo wcześniejszego leczenia i nie ma innych skutecznych opcji.
- •Specyficzne typy guzów (czerniak, rak jelita grubego) wymagały wcześniejszego określonego leczenia.
- •W przypadku czerniaka z mutacją BRAF V600: wcześniejsze leczenie inhibitorem BRAF, inhibitorem MEK i lekiem immunokompetentnym.
✗ Disqualifies
- •Przerzuty do mózgu większe niż 4 cm.
- •Trwająca terapia przeciwnowotworowa na początku badania.
- •Problemy ze wzrokiem związane z naczyniami siatkówki (np. zakrzep żyły siatkówki) lub czynniki ryzyka ich wystąpienia.
- •Choroby mięśni i nerwów powiązane z podwyższonym poziomem enzymu CK.
Simplified criteria — AI translation
Trial details
- Minimum age
- 16 Years
- Last updated (source)
- July 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (40)
Highlands Oncology Group
Fayetteville, United States
Highlands Oncology Group
Rogers, United States
Highlands Oncology Group
Springdale, United States
Clinical and Translational Research Center (CTRC)
Aurora, United States
UCHealth Sue Anschutz-Rodgers Eye Center
Aurora, United States
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)
Aurora, United States
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
Aurora, United States
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
Aurora, United States
Sylvester Comprehensive Cancer Center
Miami, United States
University of Miami Hospital and Clinics
Miami, United States
Brigham and Women's Hospital
Boston, United States
Dana-Farber Cancer Institute
Boston, United States
Dana-Farber Cancer Institute - Chestnut Hill
Newton, United States
Brigitte Harris Cancer Pavilion
Detroit, United States
Henry Ford Hospital
Detroit, United States
Henry Ford Medical Center - Columbus
Novi, United States
CT Scan and Echo Only: Henry Ford Medical Center-Plymouth
Plymouth, United States
MSK Monmouth
Middletown, United States
MSK David H. Koch Center for Cancer Care
New York, United States
Memorial Sloan Kettering Cancer Center 53rd street
New York, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Cleveland Clinic Taussig Cancer Center Investigational Pharmacy
Cleveland, United States
Cleveland Clinic
Cleveland, United States
Providence Cancer Institute Franz Clinic
Portland, United States
Providence Portland Medical Center
Portland, United States
Sarah Cannon Research Institute - Pharmacy
Nashville, United States
SCRI Oncology Partners
Nashville, United States
TriStar Bone Marrow Transplant
Nashville, United States
TriStar Centennial Medical Center - Cell Processing Lab
Nashville, United States
TriStar Centennial Medical center
Nashville, United States
START San Antonio
San Antonio, United States
The Ottawa Hospital - General Campus
Ottawa, Canada
Princess Margaret Cancer Centre
Toronto, Canada
University Health Network
Toronto, Canada
Jewish General Hospital
Montreal, Canada
McGill University Health Centre
Montreal, Canada
Sourasky Medical Center
Tel Aviv, Israel
Hadassah Medical Center
Jerusalem, Israel
Sheba Medical Center
Ramat Gan, Israel
Rambam Health Care Campus
Haifa, Israel
Trial contact
Pfizer CT.gov Call Center
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.